

Endo Documents – Annotated Bibliography

These documents and articles may be useful in understanding the context of the Endo litigation.

Select Background Regarding General Opioid Litigation and Study

1. Minhee, C. (2025). [Opioid Settlement Tracker](#).
Tracks opioid-related litigation to determine whether settlements are being used to support public health efforts. Includes FAQs, timelines, and analysis.

Select Background Focused on Endo

1. United States Food and Drug Administration. (2017, June 08). [FDA requests removal of Opana ER for risks related to abuse](#).

Discusses the FDA's decision in June 2017 to request the voluntary removal of Endo's reformulated Opana ER from the market due to its potential for non-medical use and associated public health risks. Details how postmarketing data revealed a shift from intranasal to intravenous use of the drug, leading to outbreaks of HIV, hepatitis C, and a rare blood disorder.

2. Endo. (2017, July 6). [Endo Provides Update On OPANA® ER](#).

Press release from Endo announces the company's decision to voluntarily withdraw Opana ER from the market following the FDA's June 2017 request, while maintaining the company's stance on the drug's safety and efficacy when used as prescribed.

3. Endo. (2024, February 29). [Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER](#).

Press release from Endo describes its February 2024 agreement with the U.S. Department of Justice to resolve criminal and civil investigations into certain past marketing of Opana ER, including a guilty plea to a misdemeanor misbranding charge and a civil settlement without admission of liability. Provides insight on how Endo's legal strategy, including bankruptcy proceedings and a reorganization plan, shaped the final terms of accountability for its role in the opioid crisis.

4. United States Department of Justice Office of Public Affairs. (2024, February 29). [Opioid Manufacturer Endo Health Solutions Inc. Agrees to Global Resolution of Criminal and Civil Investigations into Sales and Marketing of Branded Opioid Drug](#).

Provides a detailed summary of Endo's legal accountability, including criminal and civil penalties for certain misbranding of its opioid product, Opana ER.

5. Endo. (2025). [History](#).

Traces Endo's evolution from a small, family-run pharmaceutical company in 1920 to a major player in the industry, shaped by acquisitions and partnerships.

6. Fernandez, B. (2022, November 22). [Malvern opioid maker Endo to be monitored by Obama's former drug czar for \\$25k a month](#). *The Philadelphia Inquirer*. (registration may be required)

Discusses appointment of an outside monitor to oversee Endo's reorganization in bankruptcy. Also includes information on restrictions on Endo following its global resolution, including limitations on promoting opioids and a cap on opioid dosages the company is allowed to manufacture and distribute.

7. Fernandez, B. and McCoy, C.R. (2024, December 17). [Endo's End Around: How One of the Nation's Largest Opioid Makers Escaped a \\$7 Billion Federal Penalty](#). *ProPublica*.

Reveals how Endo avoided paying up to \$7 billion in federal penalties by leveraging bankruptcy and a corporate restructuring plan, ultimately settling for \$200 million. Provides insight into the Justice Department's delayed prosecution and Endo's financial maneuvers.